NO Market Growth Nu-Med Plus is developing nitric oxide delivery systems intended for high growth markets including cardiovascular therapy, respiratory support, wound care, and infectious diseases such as malaria and TB. Sales opportunities exist with hospitals, heart centers, NICUs, and wound care clinics seeking innovative, precision NO therapies and early access programs.

Quality Advantage The company launched an ISO 13485 certification program, signaling a commitment to medical device quality. This positions Nu-Med Plus as a favorable supplier for distributors and GPOs who require robust quality management and can speed onboarding for new customers in regulated markets.

Scale Partnerships With a lean team, Nu-Med Plus is likely to pursue contract manufacturing, OEM partnerships, or co development arrangements to scale production. This creates selling points for contract manufacturers, device integrators, and distributors looking for ready-to-scale NO delivery platforms and regulatory support.

Pipeline Collaborations A strong pipeline and patent-centric approach invites collaboration with clinical researchers, hospitals, and medical device companies for joint development, clinical trials, and dashboard integration, enabling early access and recurring revenue through pilots and deployments.

Global Expansion Global market readiness, backed by ISO alignment and a unique nitric oxide delivery technology, presents opportunities to engage international distributors, healthcare networks, and RFPs across regions seeking innovative respiratory and cardiovascular solutions, particularly in underserved markets.